A selective inhibitor of SPHK2 (Ki = 9.8 μM); inhibits SPHK2 in a dose-dependent manner (IC50 = 60 μM) without affecting SPHK1 activity at concentrations up to 100 μM; decreases [3H]S1P production in MDA-MB-231 cells in a dose-dependent manner; inhibits proliferation of human tumor cell lines (IC50s = 6-48 μM); reduces A-498 cell migration via reduction of actin filament polymerization; reduces growth of mammary adenocarcinoma xenografts in mice in a dose-dependent manner; attenuates progression of TNBS-induced inflammatory bowel disease in mice and rats